Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its fourth quarter and full year 2021 financial results on February 8, 2022, followed by a live conference call at 4:30 PM ET. Interested parties can join the call by dialing (866) 930-5479 or accessing the webcast on the company’s website. Deciphera focuses on developing innovative cancer therapies, including QINLOCK®, approved in several regions worldwide for treating fourth-line GIST.

Positive

• QINLOCK® is approved in multiple regions including the US, EU, Canada, and Australia.
• The upcoming earnings release and conference call may provide insights into revenue and growth potential.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, February 8, 2022, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 8293127. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220201005106/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals report its financial results for Q4 2021?

Deciphera Pharmaceuticals will report its Q4 2021 financial results on February 8, 2022.

What time is the Deciphera Pharmaceuticals conference call on February 8, 2022?

The conference call will take place at 4:30 PM ET on February 8, 2022.

How can I access the conference call for Deciphera Pharmaceuticals?

You can access the conference call by dialing (866) 930-5479 for domestic calls or (409) 216-0603 for international calls.

What is QINLOCK® used for?

QINLOCK® is a switch-control inhibitor used for the treatment of fourth-line GIST.

In which regions is QINLOCK® approved?

QINLOCK® is approved in the US, EU, Canada, Australia, China, Hong Kong, Switzerland, Taiwan, and the UK.